Top Value Stocks To Invest In Right Now

After perusing SolarCity’s (SCTY) third-quarter 10-Q, Axiom Capital’s Gordon Johnson contends Tesla Motors (TSLA) investors either “lack a very basic understanding of the solar market, or…lack a very basic understanding of accounting.” He explains why:

Agence France-Presse/Getty Images

While we previously pegged the odds of Teslas proposed merger ofSolarCity at a 50/50 probability yes/no, we now peg those same odds at 70/30. However, with an 0.11x exchange ofTesla stock for each share of SolarCity, if the deal were to close today,SolarCity would be valued at $20.21/share, or 2.0% upside. However, were the deal not to close, we believe SolarCitys stock would trade down to $6/share (we believeSolarCity is still creating negative value for each system sold on an unlevered basis. Thus, on valuation, applying 70% to $20.21 + 30% to $6, on arrives at a probability adjusted year-end 2016 price target of $16, or 20% downside.

Top Value Stocks To Invest In Right Now: Navios Maritime Partners LP(NMM)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Meanwhile, Safe Bulkers, Inc. (NYSE: SB) rose $0.73 throughout the 2016, Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) fell $1.69 and Navios Maritime Partners L.P. (NYSE: NMM) dropped $0.93.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

Top Value Stocks To Invest In Right Now: Internap Network Services Corporation(INAP)

Advisors’ Opinion:

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

  • [By Lisa Levin]

    Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 28 percent to $2.32 as the company reported that it has raised $43 million in a common equity private placement.

  • [By Lisa Levin]

    Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 13 percent to $2.97 on strong quarterly results. Stifel Nicolaus upgraded Internap from Hold to Buy and raised the price target from $2.00 to $5.50.

Top Value Stocks To Invest In Right Now: Fitbit, Inc.(FIT)

Advisors’ Opinion:

  • [By Paul Ausick]

    Fitbit Inc. (NYSE: FIT) lost about 2.4% Tuesday to post a new 52-week low of $8.20 after closing Monday at $8.40. The 52-week high is $34.68. Volume of around 7.1 million was about 30% below the daily average of around 1 million shares traded. The company had no specific news Tuesday.

  • [By Chris Lange]

    Fitbit, Inc. (NYSE: FIT) reported fourth-quarter financial results after the markets closed on Wednesday. So far year to date the stock is down about 20%, and down even further when looking at the past 52-weeks.Theres no doubt that this stock has taken a beating in this time, but are traders finally coming around and calling a bottom to this stock?

  • [By Peter Graham]

    Small cap fitnessdevice stockFitbit Inc (NYSE: FIT) reportedQ2 2017 earnings after the market closed Wednesday ascompetition in the fitness device and wearables market meansthe Company still has elevated short interest of 27.86% according to Highshortinterest.com. Revenue was $353.3 million versus $586.5 million (the third straight quarterly decline) asUS revenue contracted 55% to $199 million, EMEA revenue grew 9% to $109 million, APAC revenue grew 46% to $21 million, and Americas excluding U.S. revenue contracted 11% to $24 million, all year-over-year from the second quarter of 2016. New products introduced in the last 12 months, Fitbit Charge 2, Fitbit Alta HR, and Fitbit Flex 2 represented 81% of revenue while the average selling price increased 4% sequentially from the first quarter of 2017 and 2% year-over-year from the second quarter of 2016 to $100.76 per device. Accessory and other revenue added the equivalent of $3.98 per device. The net loss was $58.2 million versusnet income of$6.3 million.

  • [By Peter Graham]

    Small cap fitnessdevice stock and wearables stockFitbit Inc (NYSE: FIT) started off as a high flyer after its 2015 IPO, but those highflying days have largely ended as you can see from its long term performance chart:

  • [By The Ticker Tape]

    While you might think you’re buying the next Amazon.com, Inc. (NASDAQ: AMZN) or Microsoft Corporation (NASDAQ: MSFT), there’s also a chance you’re buying the next Fitbit (FIT) or drkoop.com. In case you’re wondering, things didn’t end very well for investors in drkoop.com’s IPO, which reached a valuation of more than $1 billion following its 1999 IPO. Drkoop.com was eventually sold for $186,000 in bankruptcy court in 2002. Fitbit investors fared slightly better, but shares have still declined approximately 70% from its IPO price of $20.00 as the company’s sales growth and profitability declined.  Not a total wash but to put that into perspective,  take a look at the  S&P 500 (SPX) which returned almost 10% during the same time period. 

Top Value Stocks To Invest In Right Now: iShares MSCI All Peru Capped ETF (EPU)

Advisors’ Opinion:

  • [By Andrew Efimoff] Related Some Positive Indexing News For A Frontier Markets ETF Why The Frontier Markets ETF Slumped Last Year Status Quo Decisions Would Bode Well For PAK ETF (Seeking Alpha)
    Related EPU Peru ETF Confronts Politics Commodities Call For The Colombia ETF Gra帽a Y Montero May Have Peaked In 2016 (Seeking Alpha) Gainers Pakistan: Global XMSCI Pakistan ETF (NYSE: PAK) is up 5.67 percent after receiving MSCI’s Emerging Markets Index approval. Peru: iShares MSCI All Peru Capped Index Fund(NYSE: EPU) is up 2.15 percent after Kuzynski won Peru’s nail-biting election. Philippines: iShares MSCI Philippines Investable(NYSE: EPHE) is up 2.21 percent after Macquarie Research said President Elect Rodrigo Duterte would lift the Pilipino property market. India: iShares MSCI India ETF (NYSE: INDA) is up 1.96 percent after India’s government relaxed regulation, making it easier for domestic airlines to fly overseas.

    Related Link: Some Positive Indexing News For A Frontier Markets ETF

  • [By Todd Shriber, ETF Professor]

    ARGT, the lone exchange traded fund dedicated to Argentine equities, is up 19.6 percent year-to-date. That is good for the second-best showing among Latin America single-country ETFs, trailing only the iShares MSCI Capped Peru Index Fund (NYSE: EPU).

Top Value Stocks To Invest In Right Now: Catabasis Pharmaceuticals, Inc.(CATB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) got a boost, shooting up 46 percent to $6.52. Catabasis Pharmaceuticals and Sarepta Therapeutics Inc (NASDAQ: SRPT) reported a joint research collaboration in Duchenne Muscular Dystrophy.

Leave a Reply

Your email address will not be published. Required fields are marked *